Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission

MeSH terms

• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / therapeutic use*
• Apoptosis / immunology*
• Brentuximab Vedotin
• CD4-Positive T-Lymphocytes / immunology
• Combined Modality Therapy
• Drug Administration Schedule
• Graft vs Host Disease / etiology
• HLA-A2 Antigen / immunology
• Hematopoietic Stem Cell Transplantation* / adverse effects
• Hodgkin Disease / drug therapy
• Hodgkin Disease / immunology*
• Hodgkin Disease / surgery
• Hodgkin Disease / therapy*
• Humans
• Immunoconjugates / administration & dosage
• Immunoconjugates / adverse effects
• Immunoconjugates / therapeutic use*
• Immunotherapy, Adoptive* / methods
• Ki-1 Antigen / antagonists & inhibitors*
• Lymphocytes / immunology*
• NK Cell Lectin-Like Receptor Subfamily B / immunology
• Polyneuropathies / chemically induced
• Recurrence
• Remission Induction
• Shock, Septic / etiology
• T-Lymphocytes / immunology*
• T-Lymphocytes, Cytotoxic / immunology
• Th17 Cells / immunology
• Thrombocytopenia / chemically induced
• Transplantation, Homologous
• Treatment Outcome